Solenn Le-Guennec

1.7k total citations
10 papers, 294 citations indexed

About

Solenn Le-Guennec is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Solenn Le-Guennec has authored 10 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Hematology and 5 papers in Molecular Biology. Recurrent topics in Solenn Le-Guennec's work include Multiple Myeloma Research and Treatments (7 papers), Peptidase Inhibition and Analysis (6 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Solenn Le-Guennec is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Peptidase Inhibition and Analysis (6 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Solenn Le-Guennec collaborates with scholars based in France, United States and Spain. Solenn Le-Guennec's co-authors include Marie‐Laure Risse, Paul G. Richardson, Frank Campana, Michel Attal, Christophe Tzourio, Neil Chapman, Kenneth C. Anderson, Stephen Harrap, Odette Poirier and John Chalmers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Solenn Le-Guennec

10 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Solenn Le-Guennec France 8 116 115 97 84 65 10 294
Beatriz Sánchez-Vega Spain 12 93 0.8× 78 0.7× 125 1.3× 106 1.3× 47 0.7× 18 421
Mu-Peng Li China 11 74 0.6× 92 0.8× 34 0.4× 112 1.3× 43 0.7× 27 332
SaeHeum Song United States 9 132 1.1× 214 1.9× 28 0.3× 133 1.6× 7 0.1× 18 501
E.A.L. Biessen Netherlands 7 49 0.4× 130 1.1× 41 0.4× 49 0.6× 38 0.6× 8 381
Stefan J. Müller Germany 7 173 1.5× 205 1.8× 226 2.3× 23 0.3× 10 0.2× 11 460
Marco Y. W. Zaki United Kingdom 9 40 0.3× 104 0.9× 19 0.2× 25 0.3× 49 0.8× 17 364
J. P. Eder United States 10 148 1.3× 143 1.2× 113 1.2× 19 0.2× 6 0.1× 21 418
Guowei Dai China 9 68 0.6× 268 2.3× 156 1.6× 9 0.1× 10 0.2× 18 451
Masato Komoda Japan 11 186 1.6× 183 1.6× 36 0.4× 16 0.2× 14 0.2× 32 408
Kevin Dietrich Canada 7 249 2.1× 179 1.6× 56 0.6× 43 0.5× 29 0.4× 14 435

Countries citing papers authored by Solenn Le-Guennec

Since Specialization
Citations

This map shows the geographic impact of Solenn Le-Guennec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Solenn Le-Guennec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Solenn Le-Guennec more than expected).

Fields of papers citing papers by Solenn Le-Guennec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Solenn Le-Guennec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Solenn Le-Guennec. The network helps show where Solenn Le-Guennec may publish in the future.

Co-authorship network of co-authors of Solenn Le-Guennec

This figure shows the co-authorship network connecting the top 25 collaborators of Solenn Le-Guennec. A scholar is included among the top collaborators of Solenn Le-Guennec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Solenn Le-Guennec. Solenn Le-Guennec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Richardson, Paul G., Simon J. Harrison, Sara Bringhen, et al.. (2021). Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study. Future Oncology. 17(34). 4797–4812. 9 indexed citations
2.
3.
Hulin, Cyrille, Paul G. Richardson, Michel Attal, et al.. (2019). Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3185–3185. 5 indexed citations
4.
Schjesvold, Fredrik, Paul G. Richardson, Michel Attal, et al.. (2019). Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood. 134(Supplement_1). 1893–1893. 8 indexed citations
5.
Richardson, Paul G., Michel Attal, S. Vincent Rajkumar, et al.. (2019). A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 37(15_suppl). 8004–8004. 16 indexed citations
6.
Richardson, Paul G., Michel Attal, Frank Campana, et al.. (2017). Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design. Future Oncology. 14(11). 1035–1047. 53 indexed citations
7.
Richardson, Paul G., Michel Attal, Jesús F. San Miguel, et al.. (2017). A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 35(15_suppl). TPS8057–TPS8057. 4 indexed citations
8.
9.
Sternberg, Cora N., Iwona Skoneczna, Daniel Castellano, et al.. (2013). Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology. 85(4). 208–215. 30 indexed citations
10.
Harrap, Stephen, Christophe Tzourio, François Cambien, et al.. (2003). The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition. Hypertension. 42(3). 297–303. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beatriz Sánchez-Vega Breakdown of academic impact, for papers by Mu-Peng Li Breakdown of academic impact, for papers by SaeHeum Song Breakdown of academic impact, for papers by E.A.L. Biessen Breakdown of academic impact, for papers by Stefan J. Müller Breakdown of academic impact, for papers by Marco Y. W. Zaki Breakdown of academic impact, for papers by J. P. Eder Breakdown of academic impact, for papers by Guowei Dai Breakdown of academic impact, for papers by Masato Komoda Breakdown of academic impact, for papers by Kevin Dietrich
Rankless by CCL
2026